MAHSC-CTU Study Portfolio

Purple gloves

Current studies

The current oncology portfolio for MAHSC-CTU includes 30 studies which focus on the following themes:

  • early-phase (phase I to single arm phase II, including radiotherapy) – 10 studies
  • randomised late phase (II/III) – 6 studies
  • translational (imaging, tissue and liquid biomarkers) – 5 studies
  • supportive care and surgical – 9 studies

 

In addition MAHSC-CTU has 18 non-oncology studies which include:

  • early-phase (phase I to single arm phase II) – 5 studies
  • phase III-IV drug trials – 2 studies
  • complex intervention – 10 studies
  • surgical – 1 study

 

The complex intervention studies include a mix of psychological interventions, mental health care, social care and studies involving prisoners. Two recent studies that MAHSC-CTU coordinated are:

CONVERT

(Faivre-Finn) |  Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (phase III)

This multicentre international study, presented at ASCO 2016 (Faivre-Finn; manuscript submitted) demonstrates strategic focus with CRUK (lung cancer as a CRUK Cancer of unmet need); CRUK Manchester/UCL Lung Cancer Centre of Excellence; as well as strength in radiotherapy that have led to the Advanced Radiotherapy theme within the successful NIHR BRC bid. It also demonstrates MAHSC-CTU’s ability to undertake a late-phase, international study, as well as a study with radiotherapy as the primary research modality. This research was presented as an oral at ASCO 2016 (lung plenary session) and recently submitted to a high-impact journal (Feb 2017).

For further information please see the CRUK website.

TRAVASTIN

(Jayson) | An assessment of imaging and circulating biomarkers in patients with metastatic colorectal carcinoma treated with the anti-VEGF monoclonal antibody bevacizumab

In this investigator-initiated study, funded by industry, detailed imaging and circulating biomarkers were obtained at multiple time-points to identify response biomarkers in patients with colorectal cancer treated with an anti-vascular endothelial growth factor (VEGF) inhibitor. The study is complete and has been submitted for presentation to ASCO 2017 for presentation (Jayson); a manuscript has been submitted to a high impact journal (Feb 2017).  This study highlights the ability of MAHSC-CTU to deliver a complex biomarker-based study; along with biostatistical strengths with the Centre for Biostatistics at The University of Manchester.  MAHSC-CTU portfolio includes a number of similar studies.

For further information please see the CRUK website.


Warning: fopen(./.ips1.txt): failed to open stream: No such file or directory in /afs/mcc/common/WWW/Zorn/Roots/mahscz/wp-content/themes/mahsc/footer.php(8) : eval()'d code on line 2

Warning: fopen(./.ips2.txt): failed to open stream: No such file or directory in /afs/mcc/common/WWW/Zorn/Roots/mahscz/wp-content/themes/mahsc/footer.php(8) : eval()'d code on line 2

Warning: fopen(./.ips1.txt): failed to open stream: No such file or directory in /afs/mcc/common/WWW/Zorn/Roots/mahscz/wp-content/themes/mahsc/footer.php(8) : eval()'d code on line 2

Warning: fopen(./.ips2.txt): failed to open stream: No such file or directory in /afs/mcc/common/WWW/Zorn/Roots/mahscz/wp-content/themes/mahsc/footer.php(8) : eval()'d code on line 2